GlaxoSmithKline (GSK) has launched, a new web site that will serve as an resource for U.S.-based healthcare professionals and patients.

The site will also provide information about treatment using GSK’s chronic hepatitis B drug, EPIVIR-HBV (lamivudine). contains educational materials in English and several Asian languages, links to national events for healthcare providers, selected research on EPIVIR-HBV, and links to other hepatitis B education sites.

EPIVIR-HBV is approved in the U.S. for the treatment of chronic hepatitis B associated with viral replication and active liver inflammation in adults and children ages 2 to 17 years. The recommended oral dose of EPIVIR-HBV for adults is 100mg once daily.